IRF9 and neoplasm: Increasing evidence suggests that JAK signaling is associated with drug resistance in tumor cells.31, 32 For example, IFNα/β activation can induce STAT1/2 and the IFN regulatory factor IRF9 in the nucleus via JAK signaling.